Editor's Note: Neuroendocrine prostate cancer (NEPC) is a hormone-refractory late manifestation of prostate cancer and represents about 25% of late-stage disease. NEPC has a poor prognosis, with most ...

NEPC, an investment consultant with $1.4 trillion in assets under advisement, on Tuesday reported a sharp increase in asset owner clients who invest with diverse managers. According to the consulting ...

A significant stake in NEPC, an investment consultant and outsourced chief investment officer, will be purchased by Hightower Holding. Merging under an umbrella entity will allow NEPC and Hightower ...

BOSTON--(BUSINESS WIRE)--NEPC, a leading research-driven investment consultant and OCIO provider with $1.4 trillion in assets under advisement, today published its third annual Diversity, Equity, and ...

NEPC saw continued progress in 2023 in making diversity, equity and inclusion work for its clients, despite an uptick in political headwinds, with goals set years before within reach and consideration ...

In a new white paper, the consultancy walks through the benefit versus cost of personalized savings advice from defined contribution managed accounts for early to mid-career savers. Consultancy NEPC’s ...

BOSTON--(BUSINESS WIRE)--NEPC, LLC, a leading investment consulting firm, is proud to announce the election of three new Partners and the designation of 10 new Principals, effective January 1, 2025.

BOSTON, March 16, 2026 /PRNewswire/ -- NEPC, LLC ("NEPC"), a leading investment consultant and outsourced chief investment officer (OCIO), today announced the launch of Stratum One, a Pooled Employer ...

Consulting firm NEPC is opening up about the work it still needs to do on diversity and inclusion. The Boston-based investment consultant on Tuesday published its first annual Diversity, Equity, and ...

NEPC, LLC is a full-service, investment consulting firm, serving more than 400 clients with over $1.9T assets under advisement. Our mission is to help governments, institutions, families, and ...

The RNA splicing factor SRRM4 drives progression of neuroendocrine prostate cancer (NEPC) and is a potential therapeutic target, say researchers. Next-generation androgen receptor pathway inhibition ...

A Mercatus Center report argues that, in response to the COVID-19 pandemic, education budgets should be reallocated toward investments in virtual schools and the pandemic is presenting Americans with ...